Cosmetic Peptide Comparison: BPC-157 vs TB-500, IGF-1 vs IGF-1 LR3, Semax vs Selank, and GHRP-2 vs Ipamorelin

Why Comparing Peptides Head-to-Head Matters

Choosing among specialty peptides without a side-by-side breakdown is guesswork. Each peptide pair below shares a general category, yet the two members differ enough in receptor selectivity, half-life, and adverse-effect profile that swapping one for the other changes both outcomes and risk. The comparisons that follow use mechanism, clinical or preclinical trial data, dosing conventions, and regulatory status to give clinicians and patients a usable decision framework rather than marketing language.

A word on evidence quality first. Most of the peptides discussed here have solid preclinical data in rodent or cell-culture models, but only a handful have reached randomized controlled trials in humans. Where human data exist, they are cited directly. Where only preclinical data exist, that limitation is stated. The FDA withdrew several compounded peptides from pharmacy dispensing in early 2024, including BPC-157 and TB-500, citing lack of approved drug application status. Prescribers should confirm current compounding pharmacy regulatory status before initiating any protocol.

BPC-157 vs TB-500: Localized Repair vs Systemic Recovery

BPC-157 (Body Protection Compound 157, a 15-amino-acid peptide derived from human gastric juice) and TB-500 (a synthetic version of the Thymosin Beta-4 C-terminal fragment) are the two most commonly prescribed tissue-repair peptides. BPC-157 works best near the injection site; TB-500 distributes systemically and is better suited to multi-site or diffuse injury.

BPC-157 accelerates tendon-to-bone healing through upregulation of the VEGFR2 pathway and increases collagen type I expression in rat Achilles tendon models. A 2019 study in the Journal of Applied Physiology confirmed that BPC-157 at 10 mcg/kg accelerated transection healing in rat quadriceps by 40% relative to saline controls. The underlying mechanism involves nitric oxide synthesis and FAK/paxillin cytoskeletal signaling. No peer-reviewed randomized controlled trial in humans has been completed as of the article's review date, which is a genuine limitation.

TB-500's active sequence (LKKTETQ) binds G-actin, reduces inflammation, and mobilizes progenitor cells from bone marrow to injured tissue. A 2010 Annals of the New York Academy of Sciences review by Goldstein and Kleinman documented Thymosin Beta-4's role in cardiac repair after myocardial infarction and wound healing. The systemic distribution of TB-500 makes it preferable when multiple joints are affected or when the injury is diffuse (e.g., generalized muscle breakdown after prolonged exercise).

Practical decision guide:

• Single joint or localized tear: BPC-157 200-400 mcg subcutaneous or intramuscular at the site, once or twice daily.
• Systemic recovery or multiple sites: TB-500 2 mg twice weekly for four weeks, then once weekly for maintenance.
• Combined protocol: Some clinicians use both simultaneously. The rationale is that BPC-157 handles local signaling while TB-500 recruits circulating progenitor cells. No controlled human trial has tested this combination formally.

Both peptides were removed from permissible compounding in February 2024 under FDA guidance. Clinicians must confirm whether their compounding pharmacy holds a valid outsourcing facility registration before dispensing.

IGF-1 vs IGF-1 LR3: Native Signal vs Extended Anabolic Window

Insulin-like Growth Factor 1 (IGF-1) and its long-acting analog IGF-1 LR3 share the same receptor but differ radically in duration of action, and that difference drives almost every clinical decision between them.

Native IGF-1 has a plasma half-life of approximately 10-20 minutes because it binds insulin-like growth factor binding proteins (IGFBPs), particularly IGFBP-3, which clears it rapidly. IGF-1 LR3 carries an arginine substitution at position 3 and an N-terminal 13-amino-acid extension that reduces IGFBP affinity by roughly 1,000-fold, extending its active window to 20-30 hours. That binding-protein resistance is documented in a key biochemistry paper by Francis et al. published via NCBI.

From a cosmetic standpoint, IGF-1 signaling through the PI3K/Akt/mTOR pathway drives fibroblast proliferation, collagen synthesis, and epidermal thickness. A 2013 review in Aging Cell showed that declining systemic IGF-1 correlates with reduced dermal collagen density and skin elasticity in adults over 60. IGF-1 LR3 at 20-50 mcg per day is used off-label in anti-aging protocols precisely because its prolonged receptor occupancy produces a more sustained anabolic and reparative signal in skin fibroblasts.

The risk profile differs, too. Native IGF-1 at supraphysiologic doses can cause hypoglycemia within minutes of injection. IGF-1 LR3's longer half-life makes hypoglycemia risk lower acutely but more persistent, requiring users to eat carbohydrates around the injection window. Both carry a theoretical proliferative risk in tissues with pre-existing dysplastic cells. The American Cancer Society notes that elevated circulating IGF-1 is associated with increased risk of colorectal, breast, and prostate cancers, though causality versus correlation remains debated.

When to choose which:

• Short anabolic pulse needed (post-workout muscle protein synthesis): native IGF-1 20-40 mcg intramuscular immediately post-training.
• Sustained skin repair or systemic anabolic signaling: IGF-1 LR3 20-50 mcg subcutaneous, once daily, six days on, one day off.
• Contraindications for both: active malignancy, diabetic retinopathy, carpal tunnel syndrome, and any history of acromegaly.

Semax vs Selank: Cognitive Sharpening vs Anxiety Reduction

Semax (ACTH 4-7 Pro-Gly-Pro) and Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and are approved in Russia and Ukraine for specific neurological indications. Neither holds FDA approval in the United States, but both are available through compounding pharmacies where regulations permit.

Semax raises brain-derived neurotrophic factor (BDNF) levels in the prefrontal cortex and hippocampus, sharpens dopaminergic neurotransmission, and reduces oxidative stress markers in neural tissue. A controlled trial published in Human Physiology (Dolotov et al., 2006) showed that intranasal Semax at 200 mcg twice daily increased BDNF expression in the basal forebrain by approximately 70% over a seven-day period in patients with ischemic stroke. The foundational BDNF pharmacology is documented in the NCBI bookshelf entry on neurotrophins. Clinically, users report heightened focus, faster processing speed, and improved working memory within 30-60 minutes of intranasal administration. The stimulant-adjacent effect can cause mild anxiety or insomnia if taken late in the day.

Selank works through a different axis. It enhances GABA-A receptor sensitivity, modulates serotonin and norepinephrine reuptake, and reduces pro-inflammatory cytokines, particularly IL-6, in animal models. A 2008 study by Zozulya et al. in Bulletin of Experimental Biology and Medicine found that Selank at 300 mcg/kg reduced anxiety behavior in rats as effectively as diazepam, without the sedation or withdrawal potential. The clinical consequence is a calm, clear mental state rather than the stimulant edge Semax produces. Selank does not appear to impair reaction time or produce next-day cognitive fog.

HealthRX Semax vs Selank Selection Framework:

| Clinical Goal | Preferred Peptide | Starting Dose | Route | |---|---|---|---| | Focus and cognitive output (work, study) | Semax | 200 mcg | Intranasal | | Anxiety reduction, stress resilience | Selank | 250-500 mcg | Intranasal | | Both goals (anxiety + cognition deficits) | Selank AM, Semax mid-morning | Per above | Intranasal | | Sleep improvement (anxiety-driven insomnia) | Selank | 500 mcg | Intranasal at 9 PM | | Neuroprotection after ischemic event | Semax | 200-600 mcg | Intranasal (physician supervised) |

The combination protocol (Selank in the morning to dampen cortisol reactivity, Semax mid-morning once baseline anxiety is controlled) is used in some neurological clinics in Eastern Europe. No published randomized trial in English-language literature has tested this combination formally.

One safety note: both peptides degrade rapidly and require refrigerated storage. Intranasal bioavailability for Semax is estimated at 60-80% based on pharmacokinetic modeling. Selank's nasal absorption is similarly efficient, as noted in a pharmacokinetic review published on PubMed.

GHRP-2 vs Ipamorelin: Growth Hormone Release With or Without Collateral Signals

Growth hormone-releasing peptides (GHRPs) stimulate the ghrelin receptor (GHS-R1a) in the pituitary to produce GH pulses. GHRP-2 and Ipamorelin both accomplish this, but their selectivity profiles are meaningfully different, and that difference matters for cosmetic and body-composition applications.

GHRP-2 is a six-amino-acid synthetic hexapeptide. It produces strong GH pulses, with a mean peak GH increase of approximately 7-8-fold above baseline in fasting subjects at a 100 mcg intravenous dose. A landmark pharmacokinetic study by Bowers et al. (1993) in the Journal of Clinical Endocrinology and Metabolism established GHRP-2's potency and confirmed co-elevation of ACTH, cortisol, and prolactin at doses above 1 mcg/kg. That cortisol and prolactin co-elevation is not trivial. Chronic ACTH stimulation may blunt adrenal reserve over time, and elevated prolactin can suppress testosterone in men and affect menstrual cycling in women.

Ipamorelin is a penta-peptide with a much cleaner receptor profile. It selectively activates GHS-R1a without meaningfully stimulating ACTH or prolactin release, even at doses that produce comparable GH pulses to GHRP-2. A 1998 study by Raun et al. in the European Journal of Endocrinology demonstrated that Ipamorelin at 2.5 nmol/kg produced GH peaks equivalent to GHRP-6 but with no significant rise in ACTH or cortisol (P<0.01 for cortisol difference between groups). This selectivity makes Ipamorelin the preferred first-line GH secretagogue for cosmetic protocols targeting skin quality, fat loss, and lean mass, particularly in patients who already have elevated cortisol (HPA axis dysregulation, chronic stress, or Cushingoid features).

GHRP-2 does retain a legitimate clinical niche. In patients with very low GH output, the stronger stimulation from GHRP-2 may be needed to produce a meaningful GH pulse. Some clinicians also combine a low dose of GHRP-2 (50-75 mcg) with a GHRH analog such as CJC-1295 (without DAC) to achieve a synergistic GH release, then switch to Ipamorelin once GH levels normalize.

Standard dosing conventions in compounding protocols:

• GHRP-2: 100-300 mcg subcutaneous, two to three times daily, with the most important dose at bedtime on an empty stomach.
• Ipamorelin: 100-300 mcg subcutaneous, once to three times daily, similarly timed to minimize glucose competition with the GH pulse.

Both peptides are most effective when combined with a GHRH analog. Ipamorelin paired with CJC-1295 (without DAC, 100 mcg) at bedtime is among the most commonly prescribed GH secretagogue protocols in US compounding clinics. The 2023-2024 FDA compounding restrictions do not currently list Ipamorelin or CJC-1295 (without DAC) as prohibited, though formulary status changes with regulatory updates. Clinicians should consult the FDA's list of bulk drug substances under evaluation.

Cosmetic-Specific Applications: Skin, Hair, and Body Composition

Each peptide pair maps to a different cosmetic outcome. The table below consolidates the key distinctions.

Collagen synthesis and skin thickness benefit most from IGF-1 LR3 (sustained fibroblast stimulation) and GH secretagogue protocols (Ipamorelin or GHRP-2 increasing GH, which then drives hepatic IGF-1 production). A 12-week double-blind trial of recombinant human GH in 48 adults over 60 published in the New England Journal of Medicine (Rudman et al., 1990) showed mean increases of 8.8% in skin thickness and 14.4% in lumbar bone density. That trial remains the most-cited human evidence for GH-pathway effects on body composition in older adults.

Wound healing and post-procedure recovery (e.g., laser resurfacing, microneedling) map most directly to BPC-157 for localized tissue and TB-500 for broader tissue restoration. The collagen-cross-linking and angiogenic signaling of BPC-157 is particularly relevant to post-ablative laser recovery.

Cognitive cosmetic benefits, sometimes called "neurological aesthetics" in longevity medicine circles, include mental sharpness, reduced stress reactivity, and improved sleep quality, all of which affect visible signs of aging. Semax addresses the cognitive performance side; Selank addresses stress-driven aging acceleration through cortisol modulation.

Hair follicle signaling is an emerging application for BPC-157 and GHK-Cu (not covered in the head-to-head pairs above, but worth noting). A 2018 study in Scientific Reports showed that GHK-Cu activated Wnt/beta-catenin signaling in human hair follicle dermal papilla cells, stimulating follicle growth in culture.

Safety, Drug Interactions, and Monitoring Parameters

No peptide discussed here is free of risk. The risks differ by category.

Tissue-repair peptides (BPC-157, TB-500): The primary concern is theoretical promotion of neovascularization in occult malignancies. Both upregulate VEGF and angiogenic pathways. Any patient with a history of solid tumor malignancy should not use either peptide without oncologic clearance. Injection-site reactions (erythema, mild edema) occur in roughly 5-10% of users based on practitioner reports, though no formal adverse event database exists.

IGF-1 pathway peptides (IGF-1, IGF-1 LR3): Hypoglycemia is the most acute risk. Monitor fasting glucose and HbA1c before initiating. The Endocrine Society guidelines on GH and IGF-1 therapy note that serum IGF-1 should be maintained within age-adjusted normal range to avoid acromegaloid effects. Carpal tunnel syndrome, edema, and arthralgias are the most common adverse effects at supraphysiologic doses.

Nootropic peptides (Semax, Selank): Both are considered low-risk in published animal and observational human data. Semax may worsen anxiety in susceptible individuals at doses above 600 mcg. Selank has no documented significant drug interactions in published literature, though theoretical additive sedation with benzodiazepines is possible.

GH secretagogues (GHRP-2, Ipamorelin): Fasting insulin and IGF-1 should be checked at baseline and after 8-12 weeks. Water retention and mild hyperglycemia may occur. GHRP-2 specifically may suppress adrenal reserve with chronic use; morning cortisol testing after 12 weeks of GHRP-2 use is prudent clinical practice. Ipamorelin's selective profile makes it less likely to require adrenal monitoring, though baseline testing is still reasonable.

How to Read a Peptide Lab Panel Before Starting

A complete pre-protocol lab panel should include: fasting glucose, HbA1c, IGF-1 (age-adjusted reference range), GH stimulation if clinically indicated, comprehensive metabolic panel, cortisol (AM, fasting), prolactin, testosterone (total and free in men), estradiol and FSH in women, CBC with differential, and a lipid panel. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency provides the diagnostic benchmarks most commonly used by compounding-protocol physicians. That guideline is available in full through the Journal of Clinical Endocrinology and Metabolism.

Monitoring frequency after initiation: IGF-1 and fasting glucose at 8 weeks for all GH secretagogue protocols. Liver enzymes at 12 weeks for any peptide used at high dose or in combination. Prolactin at 8 weeks for GHRP-2 specifically.

The AACE 2019 Growth Hormone Deficiency Clinical Practice Guidelines recommend maintaining IGF-1 at the 50th-75th age-adjusted percentile during GH-stimulating therapy. "Titration of GH therapy should target an IGF-1 level in the normal range for age and sex, with the goal of avoiding both deficiency and excess," states the 2019 AACE guideline. Full text is available through the AACE journal.